Approximately 75% of breast cancers express estrogen receptor α (ER) [2] and rely on estrogens for their proliferation, survival, and progression; therefore, inhibition of ER activity or estrogen production are common therapeutic strategies. The gene discussed is ESR1; the disease is breast carcinoma.